RE:Pfizer acquired preclinical Trillium for US$ 2.3 BlnWith Pfizer's acquisition of the preclinical CD47 company Trillium Therapeutics for US$ 2.3 Billion, and with today's news that Roche financially supported CD47 start-up company Arch Oncology has given up and laid off all of its employees, suggesting that CD47 is not a viable cancer target, and with both Pfizer and Roche facing looming patent cliffs in the foreseeable future, ONCY's pelareorep is a quick win "Phase 3 ready" acquisition target in at least 2 indications with unmet medical need, which further strengthens the proposition that ONCY's acquisition value is north of US$8 Billion, as outlined in previous posts.